Patients with chronic rhinosinusitis (CRS) with nasal polyps exhibited significant improvement in olfactory function when treated with a combination of oral and nasal steroids vs nasal steroids alone.
Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) exhibited significant improvement in olfactory function when treated with a combination treatment of oral and nasal steroids vs nasal steroids alone after 24 weeks. Results were published in European Annals of Otorhinolaryngology, Head and Neck Diseases.
Cited by patients with CRSwNP as the most prominent symptom they wish to restore, olfactory dysfunction is estimated to occur in 60% to 80% of those with the condition. Despite the availability of several interventions in the management of CRSwNP, researchers note that there is no consensus regarding the optimal medical approach to ensure adequate and long-term disease control for patients with smell impairment as the dominant symptom.
“Olfactory impairment is caused by mucosal inflammation, as well as mechanical obstruction of the olfactory cleft by polyps,” explained the study authors. “Medical treatment options for nasal polyps include topical and systemic steroids, short and long-term antibiotics, and additional care with antihistamines, antileukotrienes, antimycotics, capsaicin, and nasal douching.”
With several trials showing a positive effect of oral steroids on olfactory outcomes in patients with CRSwNP, they sought to explore the effects of oral dexamethasone plus intranasal steroids (INCS) vs INCS alone.
In the prospective randomized nonblinded study, patients with CRSwNP experiencing hyposmia (N = 140; 53.4% men) were recruited from the Outpatient Clinic and the Allergy and Endoscopy Clinic of the Otorhinolaryngology Department of Chania General Hospital in Greece.
Participants were divided into 2 groups, in which group A (n = 20) received a 7-day course of oral steroids with a 12-week course of nasal steroids and douching, and group B (n = 70) received a 12-week course of nasal steroids and douching.
The main objective of the study was to compare the olfactory effect of the different therapies in group A and group B at 2, 12, and 24 weeks, measured via Sniffin’ Sticks identification test and visual analogue scale score for olfaction (VASsmell). Several secondary objectives were also explored:
After 2 weeks, a statistically significant difference was observed between groups A and B for all parameters except VASdis (P < .001). Moreover, olfactory outcomes (Sniffin’ Sticks and VASsmell scale scores) were significantly improved in group A vs group B at the 24-week evaluation (P < .001).
Regarding effect duration within the groups, the therapeutic result remained stable between the 12-week and 24-week evaluations (P > .05). The Sniffin’ Sticks identification test score further showed a signficant correlation at the 12-week evaluation with the endoscopic appearance score system (rho = 0.58; P < .001), but not with SNOT22-Gr (rho = 0.3; P = .012).
“According to our exclusion criteria, in carefully selected and strictly instructed patients with CRSwNP, a low-dose 7-day course of oral dexamethasone may achieve a favorable outcome regarding olfaction and health-related quality of life for at least half a year,” concluded the study authors.
Reference
Papadakis CE, Chimona TS, Chaidas K, Ladias A, Zisoglou M, Proimos EK. Effect of oral steroids on olfactory function in chronic rhinosinusitis with nasal polyps. Eur Ann Otorhinolaryngol Head Neck Dis. 2021;138(5):343-348. doi:10.1016/j.anorl.2020.06.028
New Insights on Breast Cancer Outcomes Among Sexual, Gender Minorities
December 7th 2023Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Refining Precision Prevention for Benign Breast Disease
December 7th 2023Many questions remain surrounding accurately classifying the risk of developing invasive breast cancer associated with the benign breast disease diagnoses of nonproliferative lesions and proliferative changes without atypia.
Read More
Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation
September 24th 2023On this episode of Managed Care Cast, we speak with the senior author of a study published in the September 2023 issue of The American Journal of Managed Care® on the importance of adequate and effective lung cancer risk factor documentation to determine a patient's eligibility for screening.
Listen
Prediction Model Identified Risk Factors for ED Visits in Patients With Lung Cancer
December 7th 2023A risk prediction model that was based on machine learning could help to make resource utilization more efficient by correctly predicting emergency department (ED) visits in patients with lung cancer.
Read More
Negotiations to extend US global HIV/AIDS relief work are deadlocked; the Biden administration delayed its rule on the proposed menthol cigarette ban until March 2024 after lobbying by civil rights groups; federal agencies have partnered with a digital health company to create an at-home test-to-treat program for flu and COVID-19.
Read More